Summary of Study ST002145
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001359. The data can be accessed directly via it's Project DOI: 10.21228/M8270X This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002145 |
Study Title | The Carbohydrate Sensing Transcription Factor ChREBP Links Mitochondrial Lipidomes to Mitochondrial Dynamics and Progression of Diabetic Nephropathy |
Study Type | Biomarker |
Study Summary | Despite recent advances, diabetic nephropathy (DN) remains a major public health concern. The precise underlying molecular mechanisms of DN remain elusive. Accumulating recent evidence suggests that mitochondrial integrity and lipid metabolism in podocytes significantly contribute to the pathogenesis of DN. However, the interplay between these two key metabolic regulators of DN is not fully understood. This study examines the role of ChREBP (carbohydrate-response element-binding protein), a master regulator of lipogenesis, on mitochondrial morphology and progression of DN. Our findings suggest that diabetic mice with podocyte-specific deletion of ChREBP are protected against mitochondrial fragmentation and progression of DN. Using liquid chromatography coupled with mass spectrometry, we identified the central role of ChREBP-induced plasmalogen phospholipids in linking mitochondrial lipidomes with mitochondrial dynamics in DN. |
Institute | University of Texas MD Anderson Cancer Center |
Last Name | Danesh |
First Name | Farhad |
Address | 1515 Holcombe Blvd, Houston ,TX77030 |
fdanesh@mdanderson.org | |
Phone | 7135634498 |
Submit Date | 2022-03-23 |
Num Groups | 3 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2022-05-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
Analysis ID | AN003511 | AN003512 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | Reversed phase | Reversed phase |
Chromatography system | Thermo Vanquish | Thermo Vanquish |
Column | Thermo Accucore C18 (100 x 2.1mm,2.6um) | Thermo Accucore C18 (100 x 2.1mm,2.6um) |
MS Type | ESI | ESI |
MS instrument type | Orbitrap | Orbitrap |
MS instrument name | Thermo Fusion Orbitrap | Thermo Fusion Orbitrap |
Ion Mode | POSITIVE | NEGATIVE |
Units | AUC/ngDNA | AUC/ngDNA |
Chromatography:
Chromatography ID: | CH002592 |
Chromatography Summary: | Mobile phase A (MPA) was 40:60 acetonitrile:0.1% formic acid in 10 mM ammonium formate. Mobile phase B (MPB) was 90:9:1 isopropanol: acetonitrile: 0.1% formic acid in 10 mM ammonium formate. The chromatographic method included a Thermo Fisher Scientific Accucore C30 column (2.6 μm, 150 x 2.1 mm) maintained at 40°C, a mobile phase flowrate of 0.200 mL/min, and a gradient elution program as follows: 0-3 min, 30% MPB; 3-13 min, 30-43% MPB; 13.1-33 min, 50-70% MPB; 33-48 min, 70-99% MPB; 48-55 min, 99% MPB; 55.1-60 min, 30% MPB. |
Instrument Name: | Thermo Vanquish |
Column Name: | Thermo Accucore C18 (100 x 2.1mm,2.6um) |
Column Temperature: | 40 |
Flow Gradient: | 0-3 min, 30% B; 3-13 min, 30-43% B; 13.1-33 min, 50-70% B; 33-48 min, 70-99% B; 48-55 min, 99% B; 55.1-60 min, 30% B |
Flow Rate: | 0.200 mL/min |
Solvent A: | 40% acetonitrile/60% water; 0.1% formic acid; 10 mM ammonium formate |
Solvent B: | 90% isopropanol/9% acetonitrile/1% water; 0.1% formic acid; 10 mM ammonium formate |
Chromatography Type: | Reversed phase |